Endo Pharms Drug Patent Portfolio
Endo Pharms owns 1 orange book drug protected by 9 US patents Given below is the list of Endo Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8871779 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds | 22 Nov, 2029 | Active |
| US7851482 | Method for making analgesics | 10 Jul, 2029 | Active |
| US8808737 | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment | 21 Jun, 2027 | Active |
| US8192722 | Abuse-proof dosage form | 15 Sep, 2025 | Active |
| US8114383 | Abuse-proofed dosage form | 08 Aug, 2024 | Expired |
| US8075872 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US8309060 | Abuse-proofed dosage form | 20 Nov, 2023 | Expired |
| US8309122 | Oxymorphone controlled release formulations | 04 Feb, 2023 | Expired |
| US8329216 | Oxymorphone controlled release formulations | 04 Feb, 2023 | Expired |
Latest Legal Activities on Endo Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Endo Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 Jul, 2024 | US8192722 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US8309060 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2024 | US8329216 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2024 | US8309122 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 22 Jan, 2024 | US8192722 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Aug, 2023 | US8114383 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 31 May, 2023 | US8075872 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Mar, 2022 | US8871779 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jan, 2022 | US8808737 (Litigated) |
|
Expire Patent
Critical
| 21 Dec, 2020 | US8309112 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Jul, 2020 | US8309112 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 May, 2020 | US8329216 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2020 | US8309060 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Apr, 2020 | US8309122 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2019 | US8192722 |
Endo Pharms's Drug Patent Litigations
Endo Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 20, 2009, against patent number US8309122. The petitioner , challenged the validity of this patent, with Huai-Hung Kao et al as the respondent. Click below to track the latest information on how companies are challenging Endo Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8329216 | January, 2014 |
FWD Entered
(22 Jul, 2015)
| Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8329216 | August, 2014 |
FWD Entered
(22 Jul, 2015)
| Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US7851482 | November, 2013 |
Terminated-Settled
(22 Jan, 2015)
| Endo Pharmaceuticals Inc. | Amneal Pharmaceuticals, LLC |
| US8309122 | January, 2014 |
Terminated-Denied
(25 Jul, 2014)
| Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US7851482 | December, 2013 |
Decision
(19 Dec, 2013)
| Jen-Sen Dung et al | |
| US8309122 | July, 2009 |
Decision
(09 Aug, 2012)
| Huai-Hung Kao et al | |
Endo Pharms Drug Patents' Oppositions Filed in EPO
Endo Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 14, 2007, by Purdue Pharma Lp. This opposition was filed on patent number EP04763834A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06706682A | Dec, 2017 | G. L. Pharma GmbH | Revoked |
| EP07751984A | Aug, 2010 | Straus, Alexander | Revoked |
| EP2005006983W | Oct, 2009 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP2005006983W | Oct, 2009 | Ypsomed AG | Patent maintained as amended |
| EP04763833A | Mar, 2008 | Purdue Pharma LP | Opposition rejected |
| EP04763834A | Dec, 2007 | Purdue Pharma LP | Opposition rejected |
Endo Pharms's Family Patents
Endo Pharms Drug List
Given below is the complete list of Endo Pharms's drugs and the patents protecting them.
1. Opana Er
Opana Er is protected by 9 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8871779 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
22 Nov, 2029
(4 years from now)
| Active |
| US7851482 | Method for making analgesics |
10 Jul, 2029
(4 years from now)
| Active |
| US8808737 | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
21 Jun, 2027
(2 years from now)
| Active |
| US8192722 | Abuse-proof dosage form |
15 Sep, 2025
(4 months from now)
| Active |
| US8114383 | Abuse-proofed dosage form |
08 Aug, 2024
(8 months ago)
| Expired |
| US8075872 | Abuse-proofed dosage form |
20 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(1 year, 5 months ago)
| Expired |
| US8309122 | Oxymorphone controlled release formulations |
04 Feb, 2023
(2 years ago)
| Expired |
| US8329216 | Oxymorphone controlled release formulations |
04 Feb, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opana Er's drug page